Curated News
By: NewsRamp Editorial Staff
October 06, 2026

NanoViricides to Present at NIBA Conference, Advancing Broad-Spectrum Antiviral NV-387

Original Source

TLDR

  • NanoViricides presents NV-387 at NIBA, a broad-spectrum antiviral in Phase 2 trials for Ebola and Mpox, offering a pipeline advantage.
  • NanoViricides uses TheraCour nanomedicine technology to develop NV-387, which is in Phase 2 trials for Ebola Bundibugyo and Mpox.
  • NanoViricides advances NV-387 for Ebola, Mpox, and measles, aiming to improve global health outcomes for underserved populations.
  • NanoViricides will present at the NIBA conference on Oct. 7, 2026, highlighting its nanomedicines for Ebola, Mpox, and measles.

Impact - Why it Matters

NanoViricides’ presentation at the NIBA Investment Conference comes at a critical time when the world needs broad-spectrum antivirals that can address multiple viral threats, from Ebola and Mpox to measles and respiratory infections. The company’s lead candidate, NV-387, is already in Phase 2 trials for Ebola Bundibugyo and Mpox in the Democratic Republic of Congo, and its planned expansion into measles—backed by FDA Orphan Drug and Rare Pediatric Disease designations—highlights the potential of a single drug to combat several high-consequence diseases. If successful, this platform could simplify treatment and stockpiling strategies for outbreaks, especially in resource-limited settings. For investors, the conference provides an opportunity to gauge the progress of a clinical-stage biotech with a diverse pipeline and a unique nanomedicine approach. The outcomes of these trials and the company’s ability to advance NV-387 will be closely watched, as they could reshape how we respond to viral epidemics and pandemics.

Summary

NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing nanomedicines for antiviral therapy, has announced it will present at the NIBA 153rd Investment Conference on October 7, 2026, in Fort Lauderdale, Florida. The company’s lead drug candidate, NV-387, is a broad-spectrum antiviral currently undergoing separate Phase 2 clinical trials in the Democratic Republic of Congo for Ebola Bundibugyo virus disease and Mpox. NanoViricides is also planning clinical trials of NV-387 for measles—for which it has received Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration—as well as for viral acute respiratory infections. The pipeline further includes NV-HHV-1 for herpesviridae viruses and NV-HIV-1 for HIV/AIDS.

NanoViricides (www.nanoviricides.com) creates special purpose nanomaterials for antiviral therapy based on its novel nanoviricide™ class of drug candidates and technology licensed from TheraCour Pharma, Inc. The company plans to develop NV-387 as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and measles. Its other advanced candidate, NV-HHV-1, targets shingles. For COVID-19, NanoViricides has developed NV-CoV-2 (API NV-387) and NV-CoV-2-R, which encapsulates remdesivir within its polymeric micelles. The company holds a worldwide exclusive perpetual license to the TheraCour® nanomedicine technology for several human viral diseases, including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex, Varicella-Zoster, Influenza, Dengue, Japanese Encephalitis, West Nile, Ebola/Marburg, and certain Coronaviruses.

To view the full press release, visit https://ibn.fm/vQCM4. The latest news and updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC. The announcement was distributed via InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN.

Source Statement

This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides to Present at NIBA Conference, Advancing Broad-Spectrum Antiviral NV-387

Blockchain registration record for this content